Skip to content

This site is intended for UK healthcare professionals only. If you are not a UK healthcare professional, please visit our dedicated site for more information at beonemedicines.co.uk

BRUKINSA logo

ASPEN study

Indication

BRUKINSA as monotherapy is indicated for the treatment of adult patients with Waldenström's macroglobulinaemia (WM) who have received at least one prior therapy, or as first-line treatment for patients unsuitable for chemo-immunotherapy.1

ASPEN was the only Phase 3 study to randomise and compare two BTK inhibitor monotherapies for the treatment of WM3,5,6

Scroll left and right to see more
  • Primary endpoint: Proportion of patients achieving a CR or a VGPR by IRC based on the response criteria updated at the 6th IWWM3
  • Secondary endpoints for Cohort 1: MRR, PFS, DOR, investigator-assessed efficacy outcomes (rate of CR or VGPR) and safety3
  • Primary endpoint: The ASPEN trial did not meet its primary endpoint. VGPRs were numerically higher with BRUKINSA3
    • There were no CRs in either treatment group in the primary analysis

Primary endpoint: CR/VGPR in patients with MYD88MUT WM*3

Adapted from Tam CS, et al. 2020.3

Scroll left and right to see more

Efficacy outcomes across genetic subgroups7

  • Median follow-up 44.4 months in Cohort 1; 42.9 months in Cohort 2

42-month PFS: Event-free rates
Cohort 1 Cohort 2
% MYD88MUT CXCR4MUT CXCR4WT MYD88WT
BRUKINSA 78% 73% 81% 54%
Ibrutinib 70% 49% 75% -
Scroll left and right to see more

Patients with a best response of CR/VGPR
Cohort 1 Cohort 2
n, (%) MYD88MUT CXCR4MUT CXCR4WT MYD88WT
BRUKINSA 37 (36) 7 (21) 29 (45) 8 (31)
Ibrutinib 25 (25) 2 (10) 22 (31) -

Adapted from Dimopoulos, et al. 2023.3

Scroll left and right to see more

Investigator-assessed response rates increased over time8

In patients treated with BRUKINSA at 84 months of follow up:

  • The ORR was 96% and the VGPR+ rate was 40%, including 2% CR, in Cohort 1 (MYD88MUT)
    • The median duration of response was not yet reached
  • The ORR was 85% and the VGPR+ rate was 31%, including 4% CR, in Cohort 2 (MYD88WT)
    • The median duration of response was 41.1 months (95% CI: 15.7%, NE)

With extended follow-up, responses with BRUKINSA remained durable8

Best overall response rates in patients with WM receiving BRUKINSA8

Cohort 1: patients with MYD88 mutation, n=102;
Cohort 2: patients with MYD88 wild type, n=28; median follow-up 69.8 months

Adapted from D'Sa, et al. 2024.8

Scroll left and right to see more

Prevalence of AEs of special interest at >36 months7

BRUKINSA (n=72); ibrutinib (n=64)‡

Adapted from Dimopoulos, et al. 2023.7

Scroll left and right to see more

Improved long-term tolerability vs ibrutinib with 44.4 months median follow-up7

  • In Cohort 1, BRUKINSA was generally well tolerated, with fewer treatment discontinuations and dose reductions vs ibrutinib:7
    • AE leading to dose reduction: 16% (16/101) vs 27% (26/98)
    • AE leading to treatment discontinuation: 9% (9/101) vs 20% (20/98)
  • In Cohort 2, 7% (2/28) patients had a dose reduction and 21% (6/28) discontinued BRUKINSA7

With extended follow-up, the tolerability profile of BRUKINSA remained consistent (n=72):¶8

There were no discontinuations due to TEAEs

Grade ≥3 and serious AESIs for BTK inhibitors were rare

Median treatment duration with BRUKINSA was 73.5 months (range: 22.3–84.2).8

Learn more about BRUKINSA:
Select an indication to learn more about BRUKINSA: